AI assistant
Synagistics Limited Remuneration Information 2026
50674_rns_2026-01-13_769dc560-95df-4bc7-bdac-0a4dc8a78089.pdf
Remuneration Information
Open in viewerOpens in your device viewer
{0}------------------------------------------------
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
WEALTHINK AI-INNOVATION CAPITAL LIMITED
華 科 智 能 投 資 有 限 公 司
(Incorporated in the Cayman Islands with limited liability) (Stock Code: 1140)
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORTS FOR THE YEAR ENDED 31 MARCH 2021 AND 31 MARCH 2022
References are made to the annual reports of Wealthink AI-Innovation Capital Limited (the "Company", together with its subsidiaries, the "Group") for the respective financial year ended 31 March 2021 (the "2020/21 Annual Report") and financial year ended 31 March 2022 (the "2021/22 Annual Report", together with the 2020/21 Annual Report, the "Annual Reports"). Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the Annual Reports.
The Company would like to provide the following supplementary information to the shareholders and potential investors of the Company in connection with the emoluments of the chief executive officer at the material times of the Annual Reports (i.e. Dr. ZHU Xianzhong ("Dr. Zhu")).
SUMMARY
Dr. Zhu was employed with the Company in the role as chief executive officer during the period of 16 December 2020 to 29 December 2021.
For the financial year ended 31 March 2021, Dr. Zhu had been entitled to HK\$1,000,000.00 as salaries and other benefits.
For the financial year ended 31 March 2022, Dr. Zhu had been entitled to HK\$1,500,000.00 as salaries and other benefits and HK\$38,439.39 as retirement benefits scheme contributions.
The Board would like to provide supplemental information regarding the emoluments paid or payable to the Directors and the chief executive as disclosed in Note 12 to the consolidated financial statements contained in the Annual Reports ("Note 12").
{1}------------------------------------------------
Note 12 for each of the 2020/21 Annual Report and the 2021/22 Annual Report shall be reinstated as follows and save as disclosed herein, all other information in the Annual Reports remains unchanged.
2020/21 ANNUAL REPORT
12. DIRECTORS', CHIEF EXECUTIVE'S AND FIVE HIGHEST PAID EMPLOYEES' EMOLUMENTS
(a) Directors' and chief executive's emoluments
Directors' and chief executive's emoluments for the year, disclosed pursuant to the applicable Listing Rules, is as follows:
| 2021 | |||||
|---|---|---|---|---|---|
| Notes | Fees HK\$'000 |
Salaries and other benefits HK\$'000 |
Equity settled share-based payments HK\$'000 |
Retirement benefits scheme contributions HK\$'000 |
Total HK\$'000 |
| 240 | – | – | – | 240 | |
| (i) | 170 | – | – | – | 170 |
| (i) | 170 | – | – | – | 170 |
| (ii) | 1,250 | – | 1,243 | – | 2,493 |
| 250 | – | – | – | 250 | |
| 250 | – | – | – | 250 | |
| 250 | – | – | – | 250 | |
| 250 | – | – | – | 250 | |
| (iii) | – | 1,000 | – | – | 1,000 |
| 2,830 | 1,000 | 1,243 | – | 5,073 | |
| Independent non-executive |
{2}------------------------------------------------
| 2020 | ||||||
|---|---|---|---|---|---|---|
| Salaries | Equity settled |
Retirement benefits |
||||
| and other | share-based | scheme | ||||
| Name | Notes | Fees | benefits | payments | contributions | Total |
| HK\$'000 | HK\$'000 | HK\$'000 | HK\$'000 | HK\$'000 | ||
| Executive directors: | ||||||
| Dr. LIU Zhiwei | 2,875 | – | – | – | 2,875 | |
| Mr. ZHANG Gaobo | (i) | 3,000 | – | – | – | 3,000 |
| Mr. ZHANG Weidong | (iv) | – | 3,749 | 38 | 18 | 3,805 |
| Mr. ZHANG Zhi Ping | (i) | 3,000 | – | – | – | 3,000 |
| Non-executive director: | ||||||
| Dr. WU Zhong | (ii) | 5,000 | – | 2,352 | – | 7,352 |
| Independent non-executive directors: |
||||||
| Mr. CHEN Yuming | 250 | – | – | – | 250 | |
| Dr. FU Weigang | 250 | – | – | – | 250 | |
| Prof. HE Jia | 250 | – | – | – | 250 | |
| Mr. KWONG Che Keung, | ||||||
| Gordon | (v) | 102 | – | – | – | 102 |
| Mr. WANG Xiaojun | 250 | – | – | – | 250 | |
| Chief executive officer: | ||||||
| Dr. ZHU Xianzhong | (iii) | – | – | – | – | – |
| 14,977 | – | 2,390 | 18 | 21,134 |
Notes:
- (i) Resigned on 16 December 2020.
- (ii) Retired on 31 August 2020.
- (iii) Appointed on 16 December 2020.
- (iv) Resigned on 10 February 2020.
- (v) Resigned on 27 August 2019.
There was no arrangement under which a director waived or agreed to waive any emoluments during the year ended 31 March 2021 (2020: nil).
{3}------------------------------------------------
(b) Directors' material interests in transactions, arrangements or contracts
No other significant transactions, arrangements and contracts in relation to the Group's business to which the Company was a party and in which a director of the Company had a material interest, whether directly or indirectly, subsisted at the end of or at any time during the year ended 31 March 2021 (2020: nil).
(c) Five highest paid employees
The five highest paid employees of the Group during the year included 1 (2020: 3) Directors whose emoluments are set out in note 12(a) to the consolidated financial statements. Details of the emoluments for the year of the remaining 4 (2020: 2) highest paid employees who are neither a director nor chief executive of the Company are as follows:
| 2021 | 2020 | |
|---|---|---|
| HK\$'000 | HK\$'000 | |
| Basic salaries and allowances | 5,195 | 5,584 |
| Discretionary bonuses | – | 1,231 |
| Equity-settled share-based payments | – | 700 |
| Retirement benefits scheme contributions | 71 | 36 |
| 5,266 | 7,551 |
The number of the highest paid employees who are not the Directors and whose emoluments falls within the following bands:
| Number of individuals | |||
|---|---|---|---|
| 2021 | 2020 | ||
| HK\$1,000,001 to HK\$1,500,000 | 3 | – | |
| HK\$1,500,001 to HK\$2,000,000 | 1 | – | |
| HK\$3,000,001 to HK\$3,500,000 | – | 1 | |
| HK\$4,000,001 to HK\$4,500,000 | – | 1 | |
| 4 | 2 |
During the year, no emoluments were paid by the Group to any of the directors or the highest paid individuals as an inducement to join or upon joining the Group or as compensation for loss of office.
{4}------------------------------------------------
2021/22 ANNUAL REPORT
12. DIRECTORS', CHIEF EXECUTIVE'S AND FIVE HIGHEST PAID EMPLOYEES' EMOLUMENTS
(a) Directors' and chief executive's emoluments
Directors' and chief executive's emoluments for the year, disclosed pursuant to the applicable Listing Rules, is as follows:
| 2022 | |||||
|---|---|---|---|---|---|
| Notes | Fees HK\$'000 |
Salaries and other benefits HK\$'000 |
Equity settled share-based payments HK\$'000 |
Retirement benefits scheme contributions HK\$'000 |
Total HK\$'000 |
| 250 | – | – | – | 250 | |
| 118 | |||||
| (ii) | 118 | – | – | – | 118 |
| 250 | – | – | – | 250 | |
| (i) | 132 | – | – | – | 132 |
| (iii) | 250 | – | – | – | 250 |
| (iii) | 250 | – | – | – | 250 |
| (vi) | – | 1,500 | – | 38 | 1,538 |
| 1,368 | 1,500 | – | 38 | 2,906 | |
| (i) | 118 | – | – | – |
{5}------------------------------------------------
| 2021 | ||||||
|---|---|---|---|---|---|---|
| Name | Notes | Fees HK\$'000 |
Salaries and other benefits HK\$'000 |
Equity settled share-based payments HK\$'000 |
Retirement benefits scheme contributions HK\$'000 |
Total HK\$'000 |
| Executive directors: | ||||||
| Dr. LIU Zhiwei | 240 | – | – | – | 240 | |
| Mr. ZHANG Gaobo | (iv) | 170 | – | – | – | 170 |
| Mr. ZHANG Zhi Ping | (iv) | 170 | – | – | – | 170 |
| Non-executive director: | ||||||
| Dr. WU Zhong | (v) | 1,250 | – | 1,243 | – | 2,493 |
| Independent non-executive directors: |
||||||
| Mr. CHEN Yuming | 250 | – | – | – | 250 | |
| Dr. FU Weigang | (i) | 250 | – | – | – | 250 |
| Prof. HE Jia | (iii) | 250 | – | – | – | 250 |
| Mr. WANG Xiaojun | (iii) | 250 | – | – | – | 250 |
| Chief executive officer: | ||||||
| Dr. ZHU Xianzhong | (vi) | – | 1,000 | – | – | 1,000 |
| 2,830 | 1,000 | 1,243 | – | 5,073 |
Notes:
- (i) Re-designated from independent non-executive director to non-executive director on 11 October 2021.
- (ii) Appointed on 11 October 2021.
- (iii) Resigned on 22 April 2022.
- (iv) Resigned on 16 December 2020.
- (v) Retired on 31 August 2020.
- (vi) Appointed on 16 December 2020 and resigned on 29 December 2021.
There was no arrangement under which a director waived or agreed to waive any emoluments during the year ended 31 March 2022 (2021: nil).
{6}------------------------------------------------
(b) Directors' material interests in transactions, arrangements or contracts
No other significant transactions, arrangements and contracts in relation to the Group's business to which the Company was a party and in which a director of the Company had a material interest, whether directly or indirectly, subsisted at the end of or at any time during the year ended 31 March 2022 (2021: nil).
(c) Five highest paid employees
The five highest paid employees of the Group during the year included no (2021: 1) Director whose emoluments are set out in note 12(a) to the consolidated financial statements. Details of the emoluments for the year of the remaining 5 (2021: 4) highest paid employees who are neither a director nor chief executive of the Company are as follows:
| 2022 | 2021 | |
|---|---|---|
| HK\$'000 | HK\$'000 | |
| Basic salaries and allowances | 5,579 | 5,195 |
| Discretionary bonuses | 1,350 | – |
| Retirement benefits scheme contributions | 87 | 71 |
| 7,016 | 5,266 |
The number of the highest paid employees who are not the Directors and whose emoluments falls within the following bands:
| Number of individuals | |||
|---|---|---|---|
| 2022 | 2021 | ||
| Nil to HK\$1,000,000 | 1 | – | |
| HK\$1,000,001 to HK\$1,500,000 | 3 | 3 | |
| HK\$1,500,001 to HK\$2,000,000 | – | 1 | |
| HK\$2,000,001 to HK\$2,500,000 | 1 | – | |
| 5 | 4 |
During the year, no emoluments were paid by the Group to any of the directors or the highest paid individuals as an inducement to join or upon joining the Group or as compensation for loss of office.
By order of the Board Wealthink AI-Innovation Capital Limited WANG Qin Chairman
Hong Kong, 13 January 2026
As of the date of this announcement, the Board comprises four non-executive Directors, namely Dr. Wang Qin, Dr. Fu Weigang, Dr. Wang Shibin and Ms. Sun Qing; and three independent nonexecutive Directors, namely Mr. Yan Xiaotian, Mr. Zhao Kai and Mr. Yang Songbin.